Raptor Pharma making CEO change

Christopher Starr, Raptor Pharma's (RPTP) CEO since 2006, will be retiring at year's end. COO Julie Anne Smith will replace him.

Starr will remain on Raptor's board following his resignation as CEO, and will conitnue to "consult on Raptor development projects."

Smith has been Raptor's COO since Sep. '12. Prior to joining Raptor, she was the sales chief for Enobia Pharma.

Comments (1)
  • joelkatz
    , contributor
    Comments (570) | Send Message
    This change is welcomed
    7 Jul 2014, 07:15 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs